并购交易中白菜价捡到的药王——修美乐(阿达木单抗)

药事纵横
03 Dec 2024

虽然K药的销售表现让人瞩目,2022年销售额突破了200亿美元,但依然没有撼动药王的地位。虽然修美乐已经接近生命周期的终点,但仍以212.4亿美元的销售额成功卫冕。截止目前,修美乐已累计为雅培/艾伯维创造了2100亿美元的销售收入,尽管受专利悬崖影响而未来销售额持续下滑,但总累计销售额依然有望突破2500亿美元。然而,如此吸金的品种,却是在并购交易中白菜价捡到的,为什么雅培偏偏是这一个幸运的宠儿?...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10